Skip to content

Kymera Therapeutics KYMR Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$69.23M+20.4%-$86.98M-5.8%-$82.18M-7.3%-$76.61M-16.8%-$65.58M+7.3%
$2.02M-0.5%$2.03M-5.4%$2.15M+3.1%$2.08M+1.8%$2.05M+3.1%
$16.01M+10.8%$14.45M-8.5%$15.8M+2.5%$15.42M+8.3%$14.23M+3.1%
-$88.84M-33.1%-$66.75M-146%-$27.11M+54.7%-$59.88M+24.3%-$79.15M-28.1%
$434K+309%$106K-41.4%$181K-74.0%$695K+48.8%$467K-50.1%
-$142.84M+63.8%-$394.4M-67.6%-$235.3M-492%$60.02M+23.5%$48.62M
$18.77M-97.3%$705.22M+1,685%$39.51M-83.9%$245.73M+95,143%$258K-90.7%
-$212.91M-187%$244.07M+209%-$222.9M-191%$245.86M+912%-$30.28M-417%
-$89.27M-33.5%-$66.85M-145%-$27.29M+54.9%-$60.58M+23.9%-$79.62M-26.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Kymera Therapeutics generate?
Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
What is Kymera Therapeutics's free cash flow?
After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
Where does Kymera Therapeutics's cash flow data come from?
Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.